Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Lung Cancer
Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00004055
- Testing
- filgrastim, paclitaxel, topotecan hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 38 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths worldwide, with small cell lung cancer (SCLC) accounting for 15-20% of all lung cancers.
- Conditions
- Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1, Expected Survival ≥3 Months
- Trial name
- NCT06554535
- Testing
- Serplulimab，Platinum-based Chemotherapy，Aspirin
- Volunteers
- 43 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as amrubicin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00132054
- Testing
- amrubicin hydrochloride, irinotecan hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Japan Multinational Trial Organization
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have refractory or…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00020202
- Testing
- FR901228
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Comparison of two combination chemotherapies in the treatment of patients with SLCL
- Trial name
- NCT00168896
- Testing
- Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
- Where
- Germany
- Volunteers
- 286 people
- Sponsor
- Charite University, Berlin, Germany
Lung Cancer
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00041054
- Testing
- carboplatin, etoposide, exisulind
- Where
- 83 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally, once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer…
- Trial name
- FIOL (NCT03804580)
- Testing
- osimertinib
- Where
- 10 sites in Denmark, Lithuania and 2 more
- Volunteers
- 100 people
- Sponsor
- Vestre Viken Hospital Trust
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Breast Cancer, Kidney Cancer
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases. PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma
- Trial name
- NCT00769990
- Testing
- genistein, radiation therapy
- Sponsor
- Masonic Cancer Center, University of Minnesota
Extensive-stage Small-cell Lung Cancer
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.
- Trial name
- NCT06306560
- Testing
- adebrelimab, famitinib, chemotherapy
- Volunteers
- 40 people
- Sponsor
- Harbin Medical University
Small Cell Lung Cancer ( SCLC )
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
This is an open-label study with two parts, a Phase I study and a randomized Phase II study. This study will be conducted at approximately ten sites in the United States. Approximately 178 patients will be enrolled in this trial.
- Trial name
- NCT02748889
- Testing
- Carboplatin, Etoposide, MPDL3280A
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Giuseppe Giaccone
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases.
- Trial name
- NCT00452634
- Testing
- Irinotecan, Cisplatin, Simvastatin
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- National Cancer Center, Korea
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
- Trial name
- MERU (NCT03033511)
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 308 sites in United States, Australia and 39 more
- Volunteers
- 748 people
- Sponsor
- AbbVie
Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only)
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer…
- Conditions
- Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer
- Trial name
- EASE (NCT07636200)
- Testing
- Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Colorado, Boulder
Lung Cancer
Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00009971
- Testing
- fenretinide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cervical Cancer
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00019084
- Testing
- aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Small-cell Lung Cancer
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
This single-arm, Phase II, multicenter study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) in combination with Apatinib+carboplatin plus (+) etoposide in…
- Trial name
- NCT04683198
- Testing
- camrelizumab, Apatinib Mesylate, Carboplatin
- Volunteers
- 69 people
- Sponsor
- Chinese Academy of Medical Sciences